<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37196074</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2375-2548</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>20</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>19</Day></PubDate></JournalIssue><Title>Science advances</Title><ISOAbbreviation>Sci Adv</ISOAbbreviation></Journal><ArticleTitle>EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination.</ArticleTitle><Pagination><StartPage>eadg6076</StartPage><MedlinePgn>eadg6076</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">eadg6076</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1126/sciadv.adg6076</ELocationID><Abstract><AbstractText>Enterovirus D68 (EV-D68) causes severe respiratory illness in children and can result in a debilitating paralytic disease known as acute flaccid myelitis. No treatment or vaccine for EV-D68 infection is available. Here, we demonstrate that virus-like particle (VLP) vaccines elicit a protective neutralizing antibody against homologous and heterologous EV-D68 subclades. VLP based on a B1 subclade 2014 outbreak strain elicited comparable B1 EV-D68 neutralizing activity as an inactivated viral particle vaccine in mice. Both immunogens elicited weaker cross-neutralization against heterologous viruses. A B3 VLP vaccine elicited more robust neutralization of B3 subclade viruses with improved cross-neutralization. A balanced CD4<sup>+</sup> T helper response was achieved using a carbomer-based adjuvant, Adjuplex. Nonhuman primates immunized with this B3 VLP Adjuplex formulation generated robust neutralizing antibodies against homologous and heterologous subclade viruses. Our results suggest that both vaccine strain and adjuvant selection are critical elements for improving the breadth of protective immunity against EV-D68.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Krug</LastName><ForeName>Peter W</ForeName><Initials>PW</Initials><Identifier Source="ORCID">0000-0002-5969-1470</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Lingshu</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-8404-4910</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shi</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Wing-Pui</ForeName><Initials>WP</Initials><Identifier Source="ORCID">0000-0001-8544-6447</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moss</LastName><ForeName>Daniel L</ForeName><Initials>DL</Initials><Identifier Source="ORCID">0000-0001-7639-7276</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Eun Sung</ForeName><Initials>ES</Initials><Identifier Source="ORCID">0000-0003-3161-1624</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fisher</LastName><ForeName>Brian E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morabito</LastName><ForeName>Kaitlyn M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0002-4849-4690</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mascola</LastName><ForeName>John R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanekiyo</LastName><ForeName>Masaru</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5767-1532</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Graham</LastName><ForeName>Barney S</ForeName><Initials>BS</Initials><Identifier Source="ORCID">0000-0001-8112-0853</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckwardt</LastName><ForeName>Tracy J</ForeName><Initials>TJ</Initials><Identifier Source="ORCID">0000-0002-0007-7169</Identifier><AffiliationInfo><Affiliation>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Sci Adv</MedlineTA><NlmUniqueID>101653440</NlmUniqueID><ISSNLinking>2375-2548</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D058425">Vaccines, Virus-Like Particle</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000080908">Broadly Neutralizing Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D030016" MajorTopicYN="Y">Enterovirus D, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058425" MajorTopicYN="Y">Vaccines, Virus-Like Particle</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080908" MajorTopicYN="N">Broadly Neutralizing Antibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>14</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37196074</ArticleId><ArticleId IdType="pmc">PMC10191429</ArticleId><ArticleId IdType="doi">10.1126/sciadv.adg6076</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J. H. Schieble, V. L. Fox, E. H. Lennette, A probable new human picornavirus associated with respiratory diseases. Am. J. Epidemiol. 85, 297–310 (1967).</Citation><ArticleIdList><ArticleId IdType="pubmed">4960233</ArticleId></ArticleIdList></Reference><Reference><Citation>G. Wang, J. Zhuge, W. Huang, S. M. Nolan, V. L. Gilrane, C. Yin, N. Dimitrova, J. T. Fallon, Enterovirus D68 subclade B3 strain circulating and causing an outbreak in the United States in 2016. Sci. Rep. 7, 1242 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430842</ArticleId><ArticleId IdType="pubmed">28455514</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Lopez, A. Lee, A. Guo, J. L. Konopka-Anstadt, A. Nisler, S. L. Rogers, B. Emery, W. A. Nix, S. Oberste, J. Routh, M. Patel, Vital signs: Surveillance for acute flaccid myelitis—United States, 2018. MMWR Morb. Mortal. Wkly Rep. 68, 608–614 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31295232</ArticleId></ArticleIdList></Reference><Reference><Citation>V. L. Gilrane, J. Zhuge, W. Huang, S. M. Nolan, A. Dhand, C. Yin, C. Salib, F. Shakil, H. Engel, J. T. Fallon, G. Wang, Biennial upsurge and molecular epidemiology of enterovirus D68 infection in New York, USA, 2014 to 2018. J. Clin. Microbiol. 58, e00284-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448634</ArticleId><ArticleId IdType="pubmed">32493783</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Duval, A. Mirand, O. Lesens, J. O. Bay, D. Caillaud, D. Gallot, A. Lautrette, S. Montcouquiol, J. Schmidt, C. Egron, G. Jugie, M. Bisseux, C. Archimbaud, C. Lambert, C. Henquell, J.-L. Bailly, Retrospective study of the upsurge of enterovirus D68 clade D1 among adults (2014-2018). Viruses 13, 1607 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8402803</ArticleId><ArticleId IdType="pubmed">34452471</ArticleId></ArticleIdList></Reference><Reference><Citation>E. B. Hodcroft, R. Dyrdak, C. Andres, A. Egli, J. Reist, D. G. M. de Artola, J. Alcoba-Florez, H. G. M. Niesters, A. Anton, R. Poelman, M. Reynders, E. Wollants, R. A. Neher, J. Albert, Evolution, geographic spreading, and demographic distribution of Enterovirus D68. PLOS Pathog. 18, e1010515 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212145</ArticleId><ArticleId IdType="pubmed">35639811</ArticleId></ArticleIdList></Reference><Reference><Citation>O. C. Murphy, C. A. Pardo, Acute flaccid myelitis: A clinical review. Semin. Neurol. 40, 211–218 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32143233</ArticleId></ArticleIdList></Reference><Reference><Citation>M. R. Vogt, P. F. Wright, W. F. Hickey, T. De Buysscher, K. L. Boyd, J. E. Crowe Jr., Enterovirus D68 in the anterior horn cells of a child with acute flaccid myelitis. N. Engl. J. Med. 386, 2059–2060 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9321432</ArticleId><ArticleId IdType="pubmed">35613028</ArticleId></ArticleIdList></Reference><Reference><Citation>S. W. Park, M. Pons-Salort, K. Messacar, C. Cook, L. Meyers, J. Farrar, B. T. Grenfell, Epidemiological dynamics of enterovirus D68 in the United States and implications for acute flaccid myelitis. Sci. Transl. Med. 13, 10.1126/scitranslmed.abd2400, (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33692131</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Fall, N. Gallagher, C. P. Morris, J. M. Norton, A. Pekosz, E. Klein, H. H. Mostafa, Circulation of enterovirus D68 during period of increased influenza-like illness, Maryland, USA, 2021. Emerg. Infect. Dis. 28, 1525–1527 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9239864</ArticleId><ArticleId IdType="pubmed">35642471</ArticleId></ArticleIdList></Reference><Reference><Citation>K. S. Benschop, J. Albert, A. Anton, C. Andres, M. Aranzamendi, B. Armannsdottir, J.-L. Bailly, F. Baldanti, G. E. Baldvinsdottir, S. Beard, N. Berginc, S. Bottcher, S. Blomqvist, L. Bubba, C. Calvo, M. Cabrerizo, A. Cavallero, C. Celma, F. Ceriotti, I. Costa, S. Cottrell, M. Del Cuerpo, J. Dean, J. L. Dembinski, S. Diedrich, J. Diez-Domingo, D. Dorenberg, E. Duizer, R. Dyrdak, D. Fanti, A. Farkas, S. Feeney, J. Flipse, C. De Gascun, C. Galli, I. Georgieva, L. Gifford, R. Guiomar, M. Honemann, N. Ikonen, M. Jeannoel, L. Josset, K. Keeren, F. X. Lopez-Labrador, M. Maier, J. McKenna, A. Meijer, B. Mengual-Chulia, S. E. Midgley, A. Mirand, M. Montes, C. Moore, U. Morley, J. L. Murk, L. Nikolaeva-Glomb, S. Numanovic, M. Oggioni, P. Palminha, E. Pariani, L. Pellegrinelli, A. Piralla, C. Pietsch, L. Pineiro, N. Rabella, P. Rainetova, S. C. U. Renteria, M. P. Romero, M. Reynders, L. Roorda, C. Savolainen-Kopra, I. Schuffenecker, A. Soynova, C. M. Swanink, T. Ursic, J. J. Verweij, J. Vila, T. Vuorinen, P. Simmonds, T. K. Fischer, H. Harvala, Re-emergence of enterovirus D68 in Europe after easing the COVID-19 lockdown, September 2021. Euro Surveill. 26, 2100998 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8646978</ArticleId><ArticleId IdType="pubmed">34763750</ArticleId></ArticleIdList></Reference><Reference><Citation>K. C. Ma, A. Winn, H. L. Moline, H. M. Scobie, C. M. Midgley, H. L. Kirking, J. Adjemian, K. P. Hartnett, D. Johns, J. M. Jones, A. Lopez, X. Lu, A. Perez, C. G. Perrine, A. E. Rzucidlo, M. L. McMorrow, B. J. Silk, Z. Stein, E. Vega; New Vaccine Surveillance Network Collaborators, A. J. Hall, Increase in acute respiratory illnesses among children and adolescents associated with rhinoviruses and enteroviruses, including enterovirus D68—United States, July-September 2022. MMWR Morb. Mortal. Wkly Rep. 71, 1265–1270 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541033</ArticleId><ArticleId IdType="pubmed">36201400</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Christy, K. Messacar, Acute flaccid myelitis associated with enterovirus D68: A review. J. Child Neurol. 34, 511–516 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31014167</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Immunization and Respiratory Diseases, “Acute flaccid myelitis (AFM): Clinical guidance for the acute medical treatment of AFM” (2022); www.cdc.gov/acute-flaccid-myelitis/hcp/clinical-management.html [accesed 14 March 2023].</Citation></Reference><Reference><Citation>M. J. Rudy, J. Frost, P. Clarke, K. L. Tyler, Neutralizing antibody given after paralysis onset reduces the severity of paralysis compared to nonspecific antibody-treated controls in a mouse model of EV-D68-associated acute flaccid myelitis. Antimicrob. Agents Chemother. 66, e0022722 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380545</ArticleId><ArticleId IdType="pubmed">35894595</ArticleId></ArticleIdList></Reference><Reference><Citation>M. R. Vogt, J. Fu, N. Kose, L. E. Williamson, R. Bombardi, I. Setliff, I. S. Georgiev, T. Klose, M. G. Rossmann, Y. A. Bochkov, J. E. Gern, R. J. Kuhn, J. E. Crowe Jr., Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease. Sci. Immunol. 5, eaba4902 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7418079</ArticleId><ArticleId IdType="pubmed">32620559</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Zhang, C. Xu, W. Dai, Y. Wang, Z. Liu, X. Zhang, X. Wang, H. Wang, S. Gong, Y. Cong, Z. Huang, Functional and structural characterization of a two-MAb cocktail for delayed treatment of enterovirus D68 infections. Nat. Commun. 12, 2904 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8131599</ArticleId><ArticleId IdType="pubmed">34006855</ArticleId></ArticleIdList></Reference><Reference><Citation>National Center for Immunization and Respiratory Diseases, “Acute flaccid myelitis: Clinicians and health departments” (2022); www.cdc.gov/acute-flaccid-myelitis/hcp/clinicians-health-departments.html [accessed 14 March 2023].</Citation></Reference><Reference><Citation>D. M. Horstmann, Control of poliomyelitis: A continuing paradox. J. Infect. Dis. 146, 540–551 (1982).</Citation><ArticleIdList><ArticleId IdType="pubmed">6288809</ArticleId></ArticleIdList></Reference><Reference><Citation>K. Chumakov, E. Ehrenfeld, V. I. Agol, E. Wimmer, Polio eradication at the crossroads. Lancet Glob. Health 9, e1172–e1175 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34118192</ArticleId></ArticleIdList></Reference><Reference><Citation>M. T. Yeh, E. Bujaki, P. T. Dolan, M. Smith, R. Wahid, J. Konz, A. J. Weiner, A. S. Bandyopadhyay, P. Van Damme, I. De Coster, H. Revets, A. Macadam, R. Andino, Engineering the live-attenuated polio vaccine to prevent reversion to virulence. Cell Host Microbe 27, 736–751.e8 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7566161</ArticleId><ArticleId IdType="pubmed">32330425</ArticleId></ArticleIdList></Reference><Reference><Citation>F. Diaz-San Segundo, G. N. Medina, C. Stenfeldt, J. Arzt, T. de Los Santos, Foot-and-mouth disease vaccines. Vet. Microbiol. 206, 102–112 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28040311</ArticleId></ArticleIdList></Reference><Reference><Citation>M. R. Vogt, J. E. Crowe Jr., Current understanding of humoral immunity to enterovirus D68. J. Pediatric Infect. Dis. Soc. 7, S49–S53 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30590621</ArticleId></ArticleIdList></Reference><Reference><Citation>J. M. Hogle, M. Chow, D. J. Filman, Three-dimensional structure of poliovirus at 2.9 A resolution. Science 229, 1358–1365 (1985).</Citation><ArticleIdList><ArticleId IdType="pubmed">2994218</ArticleId></ArticleIdList></Reference><Reference><Citation>M. G. Murray, R. J. Kuhn, M. Arita, N. Kawamura, A. Nomoto, E. Wimmer, Poliovirus type 1/type 3 antigenic hybrid virus constructed in vitro elicits type 1 and type 3 neutralizing antibodies in rabbits and monkeys. Proc. Natl. Acad. Sci. U.S.A. 85, 3203–3207 (1988).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC280172</ArticleId><ArticleId IdType="pubmed">2834736</ArticleId></ArticleIdList></Reference><Reference><Citation>A. Meijer, S. van der Sanden, B. E. P. Snijders, G. Jaramillo-Gutierrez, L. Bont, C. K. van der Ent, P. Overduin, S. L. Jenny, E. Jusic, H. G. A. M. van der Avoort, G. J. D. Smith, G. A. Donker, M. P. G. Koopmans, Emergence and epidemic occurrence of enterovirus 68 respiratory infections in The Netherlands in 2010. Virology 423, 49–57 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22177700</ArticleId></ArticleIdList></Reference><Reference><Citation>E. B. Hodcroft, R. A. Neher, R. Dyrdak, J. Albert, “Phylodynamics of enterovirus D68” (2022); https://nextstrain.org/enterovirus/d68/genome [accessed 14 March 2023].</Citation></Reference><Reference><Citation>P.-Y. Lim, A. C. Hickey, M. F. Jamiluddin, S. Hamid, J. Kramer, R. Santos, K. N. Bossart, M. J. Cardosa, Immunogenicity and performance of an enterovirus 71 virus-like-particle vaccine in nonhuman primates. Vaccine 33, 6017–6024 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26271825</ArticleId></ArticleIdList></Reference><Reference><Citation>L. Sherry, K. Grehan, J. S. Snowden, M. L. Knight, O. O. Adeyemi, D. J. Rowlands, N. J. Stonehouse, Comparative molecular biology approaches for the production of poliovirus virus-like particles using Pichia pastoris. mSphere 5, e00838-19 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067596</ArticleId><ArticleId IdType="pubmed">32161150</ArticleId></ArticleIdList></Reference><Reference><Citation>M. W. Bahar, C. Porta, H. Fox, A. J. Macadam, E. E. Fry, D. I. Stuart, Mammalian expression of virus-like particles as a proof of principle for next generation polio vaccines. NPJ Vaccines 6, 5 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7794334</ArticleId><ArticleId IdType="pubmed">33420068</ArticleId></ArticleIdList></Reference><Reference><Citation>M. Puckette, V. Primavera, E. Martel, J. Barrera, W. Hurtle, B. Clark, B. Kamicker, M. Zurita, D. Brake, J. Neilan, Transiently transfected mammalian cell cultures: An adaptable and effective platform for virus-like particle-based vaccines against foot-and-mouth disease virus. Viruses 14, 989 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9147724</ArticleId><ArticleId IdType="pubmed">35632734</ArticleId></ArticleIdList></Reference><Reference><Citation>W. Dai, C. Zhang, X. Zhang, P. Xiong, Q. Liu, S. Gong, L. Geng, D. Zhou, Z. Huang, A virus-like particle vaccine confers protection against enterovirus D68 lethal challenge in mice. Vaccine 36, 653–659 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29295756</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Zhang, X. Zhang, W. Zhang, W. Dai, J. Xie, L. Ye, H. Wang, H. Chen, Q. Liu, S. Gong, L. Geng, Z. Huang, Enterovirus D68 virus-like particles expressed in Pichia pastoris potently induce neutralizing antibody responses and confer protection against lethal viral infection in mice. Emerg. Microbes Infect. 7, 3 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5837163</ArticleId><ArticleId IdType="pubmed">29323105</ArticleId></ArticleIdList></Reference><Reference><Citation>H. Dong, H.-C. Guo, S.-Q. Sun, Virus-like particles in picornavirus vaccine development. Appl. Microbiol. Biotechnol. 98, 4321–4329 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24647496</ArticleId></ArticleIdList></Reference><Reference><Citation>A. M. King, B. O. Underwood, D. McCahon, J. W. Newman, F. Brown, Biochemical identification of viruses causing the 1981 outbreaks of foot and mouth disease in the UK. Nature 293, 479–480 (1981).</Citation><ArticleIdList><ArticleId IdType="pubmed">6273731</ArticleId></ArticleIdList></Reference><Reference><Citation>F. Brown, Review of accidents caused by incomplete inactivation of viruses. Dev. Biol. Stand. 81, 103–107 (1993).</Citation><ArticleIdList><ArticleId IdType="pubmed">8174792</ArticleId></ArticleIdList></Reference><Reference><Citation>B. A. Phillips, In vitro assembly of poliovirus. II. Evidence for the self-assembly of 14 S particles into empty capsids. Virology 44, 307–316 (1971).</Citation><ArticleIdList><ArticleId IdType="pubmed">4105254</ArticleId></ArticleIdList></Reference><Reference><Citation>W. J. Evans, B. L. Hurst, C. J. Peterson, A. J. Van Wettere, C. W. Day, D. F. Smee, E. B. Tarbet, Development of a respiratory disease model for enterovirus D68 in 4-week-old mice for evaluation of antiviral therapies. Antiviral Res. 162, 61–70 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6997929</ArticleId><ArticleId IdType="pubmed">30521834</ArticleId></ArticleIdList></Reference><Reference><Citation>C. Zhang, X. Zhang, W. Dai, Q. Liu, P. Xiong, S. Wang, L. Geng, S. Gong, Z. Huang, A mouse model of enterovirus D68 infection for assessment of the efficacy of inactivated vaccine. Viruses 10, 58 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5850365</ArticleId><ArticleId IdType="pubmed">29385753</ArticleId></ArticleIdList></Reference><Reference><Citation>C. C. Holm-Hansen, S. E. Midgley, T. K. Fischer, Global emergence of enterovirus D68: A systematic review. Lancet Infect. Dis. 16, e64–e75 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26929196</ArticleId></ArticleIdList></Reference><Reference><Citation>H. C. Howson-Wells, T. Tsoleridis, I. Zainuddin, A. W. Tarr, W. L. Irving, J. K. Ball, L. Berry, G. Clark, C. P. McClure, Enterovirus D68 epidemic, UK, 2018, was caused by subclades B3 and D1, predominantly in children and adults, respectively, with both subclades exhibiting extensive genetic diversity. Microb. Genom. 8, mgen000825 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9465064</ArticleId><ArticleId IdType="pubmed">35532121</ArticleId></ArticleIdList></Reference><Reference><Citation>M. S. Vermillion, J. Dearing, Y. Zhang, D. R. Adney, R. H. Scheuermann, A. Pekosz, E. B. Tarbet, Animal models of enterovirus D68 infection and disease. J. Virol. 96, e0083322 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9364802</ArticleId><ArticleId IdType="pubmed">35852353</ArticleId></ArticleIdList></Reference><Reference><Citation>Q. Zheng, R. Zhu, L. Xu, M. He, X. Yan, D. Liu, Z. Yin, Y. Wu, Y. Li, L. Yang, W. Hou, S. Li, Z. Li, Z. Chen, Z. Li, H. Yu, Y. Gu, J. Zhang, T. S. Baker, Z. H. Zhou, B. S. Graham, T. Cheng, S. Li, N. Xia, Atomic structures of enterovirus D68 in complex with two monoclonal antibodies define distinct mechanisms of viral neutralization. Nat. Microbiol. 4, 124–133 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6727974</ArticleId><ArticleId IdType="pubmed">30397341</ArticleId></ArticleIdList></Reference><Reference><Citation>A. M. Hixon, G. Yu, J. S. Leser, S. Yagi, P. Clarke, C. Y. Chiu, K. L. Tyler, A mouse model of paralytic myelitis caused by enterovirus D68. PLOS Pathog. 13, e1006199 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5322875</ArticleId><ArticleId IdType="pubmed">28231269</ArticleId></ArticleIdList></Reference><Reference><Citation>J. D. Morrey, H. Wang, B. L. Hurst, K. Zukor, V. Siddharthan, A. J. Van Wettere, D. G. Sinex, E. B. Tarbet, Causation of acute flaccid paralysis by myelitis and myositis in enterovirus-D68 infected mice deficient in interferon αβ/γ receptor deficient mice. Viruses 10, 33 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5795446</ArticleId><ArticleId IdType="pubmed">29329211</ArticleId></ArticleIdList></Reference><Reference><Citation>M. G. Rossmann, The canyon hypothesis. J. Biol. Chem. 264, 14587–14590 (1989).</Citation><ArticleIdList><ArticleId IdType="pubmed">2670920</ArticleId></ArticleIdList></Reference><Reference><Citation>P. D. Minor, Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161, 121–154 (1990).</Citation><ArticleIdList><ArticleId IdType="pubmed">2169382</ArticleId></ArticleIdList></Reference><Reference><Citation>Y. Fang, Q. Chen, H. Wang, L. Wang, H. Rong, Q. Liao, C. Dong, The role of conformational epitopes in the evolutionary divergence of enterovirus D68 clades: A bioinformatics-based study. Infect. Genet. Evol. 93, 104992 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34242773</ArticleId></ArticleIdList></Reference><Reference><Citation>E. P. Parker, N. A. Molodecky, M. Pons-Salort, K. M. O'Reilly, N. C. Grassly, Impact of inactivated poliovirus vaccine on mucosal immunity: Implications for the polio eradication endgame. Expert Rev. Vaccines 14, 1113–1123 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4673562</ArticleId><ArticleId IdType="pubmed">26159938</ArticleId></ArticleIdList></Reference><Reference><Citation>R. A. Livingston, C. J. Harrison, R. Selvarangan, Neutralizing enterovirus D68 antibodies in children after 2014 outbreak, Kansas City, Missouri, USA. Emerg. Infect. Dis. 28, 539–547 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8888215</ArticleId><ArticleId IdType="pubmed">35201738</ArticleId></ArticleIdList></Reference><Reference><Citation>M. C. Freeman, A. I. Wells, J. Ciomperlik-Patton, M. M. Myerburg, L. Yang, J. Konopka-Anstadt, C. B. Coyne, Respiratory and intestinal epithelial cells exhibit differential susceptibility and innate immune responses to contemporary EV-D68 isolates. eLife 10, e66687 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8285104</ArticleId><ArticleId IdType="pubmed">34196272</ArticleId></ArticleIdList></Reference><Reference><Citation>S. K. P. Lau, C. C. Y. Yip, P. S.-H. Zhao, W.-N. Chow, K. K. W. To, A. K. L. Wu, K.-Y. Yuen, P. C. Y. Woo, Enterovirus D68 infections associated with severe respiratory illness in elderly patients and emergence of a novel clade in Hong Kong. Sci. Rep. 6, 25147 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4848506</ArticleId><ArticleId IdType="pubmed">27121085</ArticleId></ArticleIdList></Reference><Reference><Citation>C. J. Harrison, W. C. Weldon, B. A. Pahud, M. A. Jackson, M. S. Oberste, R. Selvarangan, Neutralizing antibody against enterovirus D68 in children and adults before 2014 outbreak, Kansas City, Missouri, USA. Emerg. Infect. Dis. 25, 585–588 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6390745</ArticleId><ArticleId IdType="pubmed">30789123</ArticleId></ArticleIdList></Reference><Reference><Citation>A. S. Price, J. L. Kennedy, T-helper 2 mechanisms involved in human rhinovirus infections and asthma. Ann. Allergy Asthma Immunol. 129, 681–691 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10316285</ArticleId><ArticleId IdType="pubmed">36002092</ArticleId></ArticleIdList></Reference><Reference><Citation>T. Jartti, K. Bonnelykke, V. Elenius, W. Feleszko, Role of viruses in asthma. Semin. Immunopathol. 42, 61–74 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7066101</ArticleId><ArticleId IdType="pubmed">31989228</ArticleId></ArticleIdList></Reference><Reference><Citation>L. Bungener, F. Geeraedts, W. Ter Veer, J. Medema, J. Wilschut, A. Huckriede, Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 26, 2350–2359 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18400340</ArticleId></ArticleIdList></Reference><Reference><Citation>K. S. Korsholm, R. V. Petersen, E. M. Agger, P. Andersen, T-helper 1 and T-helper 2 adjuvants induce distinct differences in the magnitude, quality and kinetics of the early inflammatory response at the site of injection. Immunology 129, 75–86 (2010).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807488</ArticleId><ArticleId IdType="pubmed">19824919</ArticleId></ArticleIdList></Reference><Reference><Citation>F. Wegmann, A. E. Moghaddam, T. Schiffner, K. H. Gartlan, T. J. Powell, R. A. Russell, M. Baart, E. W. Carrow, Q. J. Sattentau, The carbomer-lecithin adjuvant adjuplex has potent immunoactivating properties and elicits protective adaptive immunity against influenza virus challenge in mice. Clin. Vaccine Immunol. 22, 1004–1012 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4550664</ArticleId><ArticleId IdType="pubmed">26135973</ArticleId></ArticleIdList></Reference><Reference><Citation>D. J. Gasper, B. Neldner, E. H. Plisch, H. Rustom, E. Carrow, H. Imai, Y. Kawaoka, M. Suresh, Effective respiratory CD8 T-cell immunity to influenza virus induced by intranasal carbomer-lecithin-adjuvanted non-replicating vaccines. PLOS Pathog. 12, e1006064 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5173246</ArticleId><ArticleId IdType="pubmed">27997610</ArticleId></ArticleIdList></Reference><Reference><Citation>W. Lee, B. Kingstad-Bakke, B. Paulson, A. Larsen, K. Overmyer, C. B. Marinaik, K. Dulli, R. Toy, G. Vogel, K. P. Mueller, K. Tweed, A. J. Walsh, J. Russell, K. Saha, L. Reyes, M. C. Skala, J. D. Sauer, D. M. Shayakhmetov, J. Coon, K. Roy, M. Suresh, Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells. PLOS Pathog. 17, e1009168 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7840022</ArticleId><ArticleId IdType="pubmed">33444400</ArticleId></ArticleIdList></Reference><Reference><Citation>K. Messacar, S. M. Hawkins, J. Baker, K. Pearce, S. Tong, S. R. Dominguez, S. Parker, Resource burden during the 2014 enterovirus D68 respiratory disease outbreak at children's hospital Colorado: An unexpected strain. JAMA Pediatr. 170, 294–297 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">26783716</ArticleId></ArticleIdList></Reference><Reference><Citation>J. Hierholzer, R. Killington, Virus isolation and quantitation, in Virology Methods Manual, B. W. J. Mahy, H. O. Kangro, Eds. (Academic Press, 1996), pp. 25–46.</Citation></Reference><Reference><Citation>S. Maciejewski, T. J. Ruckwardt, K. M. Morabito, B. M. Foreman, K. E. Burgomaster, D. N. Gordon, R. S. Pelc, C. R. DeMaso, S.-Y. Ko, B. E. Fisher, E. S. Yang, D. Nair, K. E. Foulds, J. P. Todd, W. P. Kong, V. Roy, M. Aleshnick, S. D. Speer, N. Bourne, A. D. Barrett, M. C. Nason, M. Roederer, M. R. Gaudinski, G. L. Chen, K. A. Dowd, J. E. Ledgerwood, G. Alter, J. R. Mascola, B. S. Graham, T. C. Pierson, Distinct neutralizing antibody correlates of protection among related Zika virus vaccines identify a role for antibody quality. Sci. Transl. Med. 12, eaaw9066 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32522807</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>